Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes.

Suppr

超能文献

作者信息

Foley J E, Ligueros-Saylan M, He Y-L, Holst J J, Deacon C F, Dunning B E, Leone-Jones A, Yu T, Kelley D E

机构信息

Novartis Pharmaceutical Corporation, One Health Plaza, East Hanover, NJ 07936, USA.

出版信息

Horm Metab Res. 2008 Oct;40(10):727-30. doi: 10.1055/s-2008-1078754. Epub 2008 Jul 2.

DOI:10.1055/s-2008-1078754

PMID:18597213

Abstract

摘要

相似文献

Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes.

Horm Metab Res. 2008 Oct;40(10):727-30. doi: 10.1055/s-2008-1078754. Epub 2008 Jul 2.

Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT.

J Clin Pharmacol. 2007 May;47(5):633-41. doi: 10.1177/0091270006299137.

[Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].

Dtsch Med Wochenschr. 2008 Oct;133(43):2233-7. doi: 10.1055/s-0028-1091266. Epub 2008 Oct 15.

[Pharmacological sheet. Vildagliptin, oral administration (GALVUS)].

J Pharm Belg. 2009 Jun(2):64-6.

The role of vildagliptin in the management of type 2 diabetes mellitus.

Ann Pharmacother. 2007 May;41(5):824-32. doi: 10.1345/aph.1H460. Epub 2007 Apr 24.

[Preclinical and clinical findings of the dipeptidyl peptidase-4 inhibitor vildagliptin].

Nihon Yakurigaku Zasshi. 2010 Nov;136(5):299-308. doi: 10.1254/fpj.136.299.

Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.

Diabetes Care. 2008 Jan;31(1):30-5. doi: 10.2337/dc07-1616. Epub 2007 Oct 18.

Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus.

Clin Pharmacokinet. 2007;46(7):577-88. doi: 10.2165/00003088-200746070-00003.

Vildagliptin does not affect C-peptide clearance in patients with type 2 diabetes.

J Clin Pharmacol. 2007 Jan;47(1):127-31. doi: 10.1177/0091270006295061.

Vildagliptin in clinical practice: a review of literature.

Expert Opin Pharmacother. 2009 Nov;10(16):2745-57. doi: 10.1517/14656560903302265.

引用本文的文献

Mitigating iftar-related glycemic excursions in adolescents and young adults with type 1 diabetes on MiniMed™ 780G advanced hybrid closed loop system: a randomized clinical trial for adjunctive oral vildagliptin therapy during Ramadan fasting.

Diabetol Metab Syndr. 2023 Dec 7;15(1):257. doi: 10.1186/s13098-023-01232-5.

Triple drug therapy with GABA, sitagliptin, and omeprazole prevents type 1 diabetes onset and promotes its reversal in non-obese diabetic mice.

Front Endocrinol (Lausanne). 2022 Oct 21;13:1028114. doi: 10.3389/fendo.2022.1028114. eCollection 2022.

Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man.

Front Endocrinol (Lausanne). 2019 Nov 8;10:780. doi: 10.3389/fendo.2019.00780. eCollection 2019.

DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.

J Diabetes Res. 2018 Jan 8;2018:5308582. doi: 10.1155/2018/5308582. eCollection 2018.

DPP-4 inhibitor treatment: β-cell response but not HbA reduction is dependent on the duration of diabetes.

Vasc Health Risk Manag. 2017 Mar 31;13:123-126. doi: 10.2147/VHRM.S125850. eCollection 2017.

[Berberine regulates glycemia local inhibition of intestinal dipeptidyl peptidase-Ⅳ].

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2016 May 25;45(5):486-492. doi: 10.3785/j.issn.1008-9292.2016.09.06.

Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism.

Diabetologia. 2016 May;59(5):907-17. doi: 10.1007/s00125-016-3899-2. Epub 2016 Feb 19.

The influence of glucagon on postprandial hyperglycaemia in children 5 years after onset of type 1 diabetes.

Diabetologia. 2015 Apr;58(4):828-34. doi: 10.1007/s00125-014-3486-3. Epub 2014 Dec 27.

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes.

Diabetes Metab Syndr Obes. 2013 May 6;6:187-95. doi: 10.2147/DMSO.S35682. Print 2013.

Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.

Drug Des Devel Ther. 2013;7:99-104. doi: 10.2147/DDDT.S38346. Epub 2013 Feb 14.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验